Trial Profile
Randomized, Double-blind, Placebo-controlled, Parallel Group, Multiple Dose, Multicenter Study to Assess Safety and Efficacy of BGP-15 Administered Orally 1 or 2 Times Daily With Metformin and Sulfonylurea or Metformin in T2 Diabetic Patients
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs BGP 15 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors N-Gene Research Laboratories
- 31 Jul 2013 Planned end date changed from 1 Nov 2011 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 10 Jul 2013 This trial has been discontinued in Hungary and has an unknown status in Germany and the USA because this information has not been verified recently in the ClinicalTrials.gov record (last verified June 2011).
- 13 May 2013 Status changed from unconfirmed to discontinued as reported by ClinicalTrials.gov.